ASH 2022 | Results from VITAL: survival benefit of birtamimab in Mayo Stage IV AL amyloidosis
Morie Gertz, MD, MACP, Mayo Clinic, Rochester, MN, describes the results of the Phase III VITAL study (NCT02312206) which showed that treatment with birtamimab and bortezomib backbone chemotherapy improved survival in patients with advanced AL cardiac amyloidosis. Following this, Dr Gertz highlights the aims of the prospective Phase III AFFIRM-AL trial (NCT04973137) which will compare treatment with chemotherapy plus birtamimab versus chemotherapy. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Ionis/Akcea: Other: personal fees; Prothena: Other: personal fees; Sanofi: Other: personal fees; Janssen: Other: personal fees; Aptitude Healthgrants: Other: personal fees; Ashfield: Other: personal fees; Juno: Other: personal fees; Physicians Education Resource: Other: personal fees; Abbvie: Membership on an entity’s Board of Directors or advisory committees, Other: personal fees from Data Safety Monitoring Board; Johnson & Johnson: Other: personal fees; Celgene: Other: personal fees; Research to Practice: Other: personal fees; Sorrento: Other: personal fees; i3Health: Other: Development of educational materials for i3Health.
